Gossamer Bio (GOSS)
Gossamer Bio on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
1.4M
Short interest
settlement 2026-10-15
5.1
Days to cover
+1.6 days vs prior
54.1%
Short share of volume
2026-11-02
12,724
Fails to deliver
settlement 2026-10-14
Wed 4 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in GOSS is 1,436,240 shares, up 487,617 shares over the last month. Over the last 48 readings it ranged from 948,623 shares (15 September 2026) to 94,986,016 shares (31 July 2026). The latest reading sits at the bottom of that range. At the reported average volume of 280K shares a day that is 5.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/goss" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 1,436,240 | +16.0% | 280,470 | 5.12 |
| 2026-09-30 | 1,237,721 | +30.5% | 353,408 | 3.50 |
| 2026-09-15 | 948,623 | -98.8% | 186,993 | 5.07 |
| 2026-08-31 | 82,633,317 | -4.8% | 29,606,971 | 2.79 |
| 2026-08-14 | 86,786,498 | -8.6% | 11,783,142 | 7.37 |
| 2026-07-31 | 94,986,016 | +29.8% | 63,584,808 | 1.49 |
| 2026-07-15 | 73,178,841 | +36.3% | 19,310,997 | 3.79 |
| 2026-06-30 | 53,695,991 | -4.5% | 16,674,771 | 3.22 |
| 2026-06-15 | 56,212,006 | -10.5% | 16,462,056 | 3.41 |
| 2026-05-29 | 62,815,917 | +53.8% | 22,102,118 | 2.84 |
| 2026-05-15 | 40,838,667 | +2.0% | 3,558,686 | 11.48 |
| 2026-04-30 | 40,018,309 | -0.4% | 5,234,457 | 7.65 |
| 2026-04-15 | 40,196,107 | +7.2% | 8,292,309 | 4.85 |
| 2026-03-31 | 37,500,300 | +2.4% | 13,614,400 | 2.75 |
| 2026-03-13 | 36,622,286 | +5.5% | 13,565,159 | 2.70 |
| 2026-02-27 | 34,715,538 | +11.7% | 44,951,614 | 1.00 |
| 2026-02-13 | 31,092,342 | +16.1% | 6,094,020 | 5.10 |
| 2026-01-30 | 26,779,236 | +6.2% | 4,713,026 | 5.68 |
| 2026-01-15 | 25,222,443 | +4.6% | 4,646,927 | 5.43 |
| 2025-12-31 | 24,114,833 | +18.7% | 5,172,180 | 4.66 |
| 2025-12-15 | 20,310,911 | -13.3% | 3,543,881 | 5.73 |
| 2025-11-28 | 23,438,565 | -4.0% | 2,852,104 | 8.22 |
| 2025-11-14 | 24,422,288 | -2.0% | 2,583,683 | 9.45 |
| 2025-10-31 | 24,918,422 | -6.9% | 3,111,094 | 8.01 |
| 2025-10-15 | 26,759,668 | -2.3% | 3,248,248 | 8.24 |
| 2025-09-30 | 27,397,216 | +14.2% | 4,255,013 | 6.44 |
| 2025-09-15 | 23,993,214 | +8.8% | 5,675,007 | 4.23 |
| 2025-08-29 | 22,046,902 | +7.5% | 3,086,575 | 7.14 |
| 2025-08-15 | 20,502,512 | +9.4% | 3,011,672 | 6.81 |
| 2025-07-31 | 18,745,165 | +3.4% | 3,633,052 | 5.16 |
| 2025-07-15 | 18,122,038 | +7.2% | 1,554,956 | 11.65 |
| 2025-06-30 | 16,906,319 | +52.6% | 3,923,520 | 4.31 |
| 2025-06-13 | 11,076,527 | -0.1% | 1,279,261 | 8.66 |
| 2025-05-30 | 11,082,536 | +5.1% | 1,669,828 | 6.64 |
| 2025-05-15 | 10,540,492 | +4.7% | 1,455,780 | 7.24 |
| 2025-04-30 | 10,069,688 | +9.8% | 1,706,356 | 5.90 |
| 2025-04-15 | 9,172,699 | +15.0% | 1,616,223 | 5.68 |
| 2025-03-31 | 7,974,056 | +38.9% | 1,467,793 | 5.43 |
| 2025-03-14 | 5,741,046 | +2.8% | 1,473,394 | 3.90 |
| 2025-02-28 | 5,587,439 | -2.3% | 1,924,148 | 2.90 |
| 2025-02-14 | 5,717,172 | -1.6% | 1,967,738 | 2.91 |
| 2025-01-31 | 5,811,407 | -7.1% | 656,247 | 8.86 |
| 2025-01-15 | 6,253,026 | +2.2% | 1,305,091 | 4.79 |
| 2024-12-31 | 6,118,359 | -12.8% | 976,052 | 6.27 |
| 2024-12-13 | 7,017,649 | +10.0% | 3,261,638 | 2.15 |
| 2024-11-29 | 6,377,139 | -2.3% | 1,097,124 | 5.81 |
| 2024-11-15 | 6,527,517 | +3.5% | 1,033,410 | 6.32 |
| 2024-10-31 | 6,304,348 | -9.3% | 629,907 | 10.01 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of GOSS volume is 54.1%, down 18.4 points over the last five sessions. Over the last 30 readings it ranged from 29.1% (22 September 2026) to 79.2% (19 October 2026). The latest reading is 5.0 points below the 30-session average of 59.0%, on 79K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 43K | 79K | 54.1% | 4,117 |
| 2026-10-30 | 38K | 63K | 60.1% | 76 |
| 2026-10-29 | 16K | 52K | 30.7% | 0 |
| 2026-10-28 | 38K | 71K | 53.7% | 470 |
| 2026-10-27 | 28K | 42K | 66.2% | 0 |
| 2026-10-26 | 82K | 113K | 72.5% | 11 |
| 2026-10-23 | 40K | 53K | 74.3% | 25 |
| 2026-10-22 | 33K | 58K | 57.0% | 61 |
| 2026-10-21 | 61K | 116K | 52.2% | 43 |
| 2026-10-20 | 32K | 67K | 47.9% | 100 |
| 2026-10-19 | 51K | 65K | 79.2% | 38 |
| 2026-10-16 | 50K | 69K | 72.8% | 1,738 |
| 2026-10-15 | 68K | 96K | 70.1% | 4,052 |
| 2026-10-14 | 95K | 143K | 66.1% | 139 |
| 2026-10-13 | 105K | 171K | 61.6% | 100 |
| 2026-10-12 | 47K | 78K | 60.1% | 301 |
| 2026-10-09 | 87K | 142K | 61.3% | 694 |
| 2026-10-08 | 50K | 79K | 63.4% | 50 |
| 2026-10-07 | 105K | 158K | 66.4% | 8 |
| 2026-10-06 | 56K | 79K | 70.8% | 13 |
| 2026-10-05 | 113K | 170K | 66.5% | 47 |
| 2026-10-02 | 53K | 73K | 73.0% | 0 |
| 2026-10-01 | 112K | 157K | 71.2% | 0 |
| 2026-09-30 | 84K | 153K | 54.9% | 400 |
| 2026-09-29 | 86K | 153K | 56.3% | 646 |
| 2026-09-28 | 107K | 237K | 45.3% | 138 |
| 2026-09-25 | 94K | 168K | 55.7% | 0 |
| 2026-09-24 | 37K | 117K | 31.4% | 7,457 |
| 2026-09-23 | 82K | 176K | 46.6% | 2,804 |
| 2026-09-22 | 22K | 75K | 29.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in GOSS is 12,724 shares, down 7,342 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (24 September 2026) to 3,535,808 shares (11 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 12,724 | $9.76 | $124K |
| 2026-10-13 | 20,066 | $9.28 | $186K |
| 2026-10-09 | 6,204 | $9.88 | $61K |
| 2026-10-08 | 8,990 | $10.18 | $92K |
| 2026-10-07 | 6,474 | $10.78 | $70K |
| 2026-10-06 | 19,691 | $10.65 | $210K |
| 2026-10-05 | 2,410 | $10.71 | $26K |
| 2026-10-02 | 94 | $10.93 | $1K |
| 2026-09-28 | 133 | $10.94 | $1K |
| 2026-09-25 | 17 | $10.93 | $186 |
| 2026-09-24 | 2 | $10.99 | $22 |
| 2026-09-23 | 1,752 | $11.69 | $20K |
| 2026-09-22 | 9,943 | $11.28 | $112K |
| 2026-09-21 | 6,487 | $10.73 | $70K |
| 2026-09-18 | 6,152 | $11.94 | $73K |
| 2026-09-17 | 1,932 | $10.96 | $21K |
| 2026-09-16 | 2,012 | $10.38 | $21K |
| 2026-09-15 | 3,544 | $10.70 | $38K |
| 2026-09-14 | 6,311 | $10.73 | $68K |
| 2026-09-11 | 3,535,808 | $0.14 | $495K |
| 2026-09-10 | 2,000 | $0.16 | $320 |
| 2026-09-08 | 26,877 | $0.18 | $5K |
| 2026-09-04 | 308,145 | $0.18 | $55K |
| 2026-09-03 | 8,504 | $0.17 | $1K |
| 2026-09-02 | 2,924 | $0.17 | $497 |
| 2026-09-01 | 25,701 | $0.17 | $4K |
| 2026-08-31 | 900 | $0.17 | $153 |
| 2026-08-27 | 7,010 | $0.17 | $1K |
| 2026-08-24 | 617,017 | $0.15 | $93K |
| 2026-08-21 | 23,949 | $0.16 | $4K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for GOSS in the last 90 days. The most recent filings are listed below. Latest filing: Smith Robert Paul JR (Chief Commercial Officer) on 2026-01-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-01-02 | Smith Robert Paul JR | Chief Commercial Officer | Grant | 94K | $0.00 | $0 | 261K |
| 2026-01-02 | Peterson Caryn | EVP, Regulatory Affairs | Grant | 85K | $0.00 | $0 | 259K |
| 2026-01-02 | Hasnain Faheem | President & CEO | Grant | 280K | $0.00 | $0 | 838K |
| 2026-01-02 | Giraudo Bryan | COO/CFO | Grant | 116K | $0.00 | $0 | 390K |
| 2026-01-02 | Christian Waage | EVP, Tech Ops and Admin | Grant | 85K | $0.00 | $0 | 814K |
| 2026-01-02 | Aranda Richard | Chief Medical Officer | Grant | 94K | $0.00 | $0 | 463K |
| 2025-10-01 | Smith Robert Paul JR | Chief Commercial Officer | Grant | 163K | $0.00 | $0 | 163K |
| 2025-10-01 | Peterson Caryn | EVP, Regulatory Affairs | Grant | 125K | $0.00 | $0 | 175K |
| 2025-10-01 | Hasnain Faheem | President & CEO | Grant | 438K | $0.00 | $0 | 558K |
| 2025-10-01 | Giraudo Bryan | COO/CFO | Grant | 181K | $0.00 | $0 | 274K |
| 2025-10-01 | Christian Waage | EVP, Tech Ops and Admin | Grant | 125K | $0.00 | $0 | 711K |
| 2025-10-01 | Aranda Richard | Chief Medical Officer | Grant | 163K | $0.00 | $0 | 369K |
| 2025-08-19 | Milligan Sandra | Director | Buy | 26K | $1.92 | $50K | 58K |
| 2024-06-24 | Aranda Richard | Chief Medical Officer | Sell | 2K | $0.66 | $1K | 197K |
| 2024-06-21 | Hasnain Faheem | President & CEO | Buy | 372K | $0.67 | $249K | 5.4M |
| 2024-06-18 | Giraudo Bryan | COO/CFO | Buy | 100K | $0.59 | $59K | 480K |
| 2024-06-17 | Smith Robert Paul JR | Chief Commercial Officer | Buy | 25K | $0.60 | $15K | 25K |
| 2024-03-27 | Hasnain Faheem | President & CEO | Sell | 23K | $1.16 | $27K | 120K |
| 2024-03-27 | Giraudo Bryan | COO/CFO | Sell | 6K | $1.16 | $7K | 93K |
| 2024-03-27 | Christian Waage | EVP, Tech Ops and Admin | Sell | 6K | $1.16 | $7K | 586K |
| 2024-03-18 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 4K | $1.33 | $5K | 50K |
| 2024-03-18 | Aranda Richard | Chief Medical Officer | Sell | 4K | $1.33 | $5K | 199K |
| 2023-11-15 | Milligan Sandra | Director | Buy | 32K | $0.79 | $25K | 32K |
| 2023-11-13 | Giraudo Bryan | COO/CFO | Buy | 200K | $0.56 | $112K | 380K |
| 2023-07-24 | Christian Waage | EVP, Tech Ops and Admin | Grant | 14K | $1.82 | $25K | 46K |
| 2023-07-24 | Hasnain Faheem | President & CEO | Grant | 540K | $1.82 | $983K | 5.0M |
| 2023-07-24 | Giraudo Bryan | COO/CFO | Grant | 54K | $1.82 | $98K | 180K |
| 2023-06-22 | Aranda Richard | Chief Medical Officer | Sell | 2K | $1.29 | $2K | 198K |
| 2023-04-04 | Giraudo Bryan | COO/CFO | Buy | 55K | $1.02 | $56K | 126K |
| 2023-03-22 | Hasnain Faheem | President & CEO | Buy | 441K | $1.14 | $502K | 4.5M |
| 2023-03-21 | Hasnain Faheem | President & CEO | Buy | 269K | $1.20 | $323K | 4.1M |
| 2023-03-20 | Hasnain Faheem | President & CEO | Buy | 169K | $1.03 | $174K | 3.8M |
| 2023-03-20 | Giraudo Bryan | COO/CFO | Buy | 50K | $0.97 | $49K | 71K |
| 2023-03-20 | Christian Waage | EVP, Tech Ops and Admin | Buy | 19K | $1.20 | $22K | 32K |
| 2023-03-16 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 8K | $1.10 | $8K | 54K |
| 2023-03-16 | Aranda Richard | Chief Medical Officer | Sell | 8K | $1.10 | $8K | 199K |
| 2023-03-16 | Carter Laura | Chief Scientific Officer | Sell | 6K | $1.10 | $7K | 76K |
| 2022-10-24 | Aranda Richard | Chief Medical Officer | Sell | 5K | $12.07 | $57K | 205K |
| 2022-10-24 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 5K | $12.07 | $57K | 61K |
| 2022-10-24 | Carter Laura | Chief Scientific Officer | Sell | 5K | $12.07 | $59K | 82K |
| 2022-07-15 | Hasnain Faheem | President & CEO | Buy | 139K | $7.21 | $1000K | 3.6M |
| 2022-07-15 | Giraudo Bryan | COO/CFO | Buy | 14K | $7.21 | $100K | 21K |
| 2022-07-15 | Christian Waage | EVP, Tech Ops and Admin | Buy | 7K | $7.21 | $50K | 14K |
| 2022-07-15 | Carter Laura | Chief Scientific Officer | Buy | 7K | $7.21 | $50K | 87K |
| 2022-07-01 | Carter Laura | Chief Scientific Officer | Sell | 9K | $8.25 | $73K | 80K |
| 2022-06-22 | Aranda Richard | Chief Medical Officer | Sell | 2K | $6.88 | $12K | 210K |
| 2022-05-04 | Carter Laura | Chief Scientific Officer | Sell | 1K | $7.20 | $9K | 89K |
| 2022-03-23 | Giraudo Bryan | COO/CFO | Sell | 11K | $8.92 | $96K | 99K |
| 2022-03-23 | Hasnain Faheem | President & CEO | Sell | 19K | $8.92 | $170K | 143K |
| 2022-03-23 | Christian Waage | EVP, Tech Ops and Admin | Sell | 11K | $8.92 | $96K | 579K |
| 2022-03-16 | Aranda Richard | Chief Medical Officer | Sell | 6K | $8.28 | $52K | 212K |
| 2022-03-16 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 6K | $8.28 | $52K | 66K |
| 2022-03-16 | Carter Laura | Chief Scientific Officer | Sell | 5K | $8.28 | $41K | 90K |
| 2021-10-25 | Aranda Richard | Chief Medical Officer | Sell | 2K | $12.25 | $29K | 217K |
| 2021-10-25 | Carter Laura | Chief Scientific Officer | Sell | 2K | $12.25 | $29K | 95K |
| 2021-10-25 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 2K | $12.25 | $29K | 72K |
| 2021-06-30 | Carter Laura | Chief Scientific Officer | Grant | 25K | $0.00 | $0 | 98K |
| 2021-06-21 | Aranda Richard | Chief Medical Officer | Grant | 15K | $0.00 | $0 | 220K |
| 2021-05-03 | Carter Laura | Chief Scientific Officer | Grant | 11K | $0.00 | $0 | 73K |
| 2021-04-16 | Peterson Caryn | EVP, Regulatory Affairs | Grant | 11K | $0.00 | $0 | 75K |
| 2021-03-23 | Christian Waage | EVP & General Counsel | Sell | 5K | $9.48 | $52K | 588K |
| 2021-03-23 | Giraudo Bryan | Chief Financial Officer | Sell | 5K | $9.48 | $52K | 110K |
| 2021-03-23 | Salter-Cid Luisa | Chief Scientific Officer | Sell | 5K | $9.48 | $52K | 206K |
| 2021-02-25 | Christian Waage | EVP & General Counsel | Grant | 45K | $0.00 | $0 | 594K |
| 2021-02-25 | Giraudo Bryan | Chief Financial Officer | Grant | 45K | $0.00 | $0 | 115K |
| 2021-02-25 | Salter-Cid Luisa | Chief Scientific Officer | Grant | 45K | $0.00 | $0 | 212K |
| 2021-02-25 | Hasnain Faheem | President & CEO | Grant | 163K | $0.00 | $0 | 163K |
| 2020-10-14 | Giraudo Bryan | Chief Financial Officer | Buy | 3K | $10.01 | $30K | 7K |
| 2020-10-14 | Hasnain Faheem | Director | Buy | 97K | $10.36 | $1000K | 3.5M |
| 2020-10-14 | Christian Waage | EVP & General Counsel | Buy | 3K | $9.53 | $24K | 7K |
| 2020-06-23 | Giraudo Bryan | Chief Financial Officer | Buy | 2K | $12.96 | $26K | 4K |
| 2020-02-14 | Gujrathi Sheila | President & CEO | Grant | 190K | $0.00 | $0 | 190K |
| 2020-02-14 | Giraudo Bryan | Chief Financial Officer | Grant | 47K | $0.00 | $0 | 70K |
| 2020-02-14 | Christian Waage | EVP & General Counsel | Grant | 47K | $0.00 | $0 | 548K |
| 2020-02-14 | Salter-Cid Luisa | Chief Scientific Officer | Grant | 47K | $0.00 | $0 | 167K |
| 2020-02-14 | Dupont Jakob | Chief Medical Officer | Grant | 47K | $0.00 | $0 | 47K |
| 2019-12-31 | Salter-Cid Luisa | Chief Scientific Officer | Gift | 4K | $0.00 | $0 | 120K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON14 holders report 5% or more of GOSS in their latest filing, all on Schedule 13G (passive). The largest reported stake is 683 Capital Partners, LP at 10.0% of the class (49,868,571 shares), filed 2026-06-11 for an event on 2026-06-04.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-29 | 13D/Ano. 6 | D. E. Shaw & Co., L.P.investment adviser, partnership | 255K | 4.2% | 2026-10-27 |
| 2026-10-29 | 13D/Ano. 6 | David E. Shawindividual | 255K | 4.2% | 2026-10-27 |
| 2026-10-29 | 13D/Ano. 6 | D. E. Shaw & Co., L.L.C.other entity | 255K | 4.2% | 2026-10-27 |
| 2026-10-29 | 13D/Ano. 6 | D. E. Shaw Valence Portfolios, L.L.C.other entity | 243K | 4.0% | 2026-10-27 |
| 2026-07-29 | 13G | Opaleye Management Inc.investment adviser, corporation | 24.9M | 5.1% | 2026-07-22 |
| 2026-07-29 | 13G | James Silvermanindividual | 24.9M | 5.1% | 2026-07-22 |
| 2026-07-29 | 13G | Opaleye, L.P.partnership | 24.1M | 4.9% | 2026-07-22 |
| 2026-07-29 | 13G/Ano. 2 | BlackRock, Inc.parent holding company | 4.9M | 1.0% | 2026-06-30 |
| 2026-06-11 | 13G | 683 Capital Partners, LPpartnership | 49.9M | 10.0% | 2026-06-04 |
| 2026-06-11 | 13G | Ari Zweimanindividual | 49.9M | 10.0% | 2026-06-04 |
| 2026-06-11 | 13G | 683 Capital Management, LLCinvestment adviser | 49.9M | 10.0% | 2026-06-04 |
| 2026-06-11 | 13G | DeepCurrents Investment Group LLCinvestment adviser | 37.7M | 7.7% | 2026-06-04 |
| 2026-06-11 | 13G | Kai Zhengparent holding company, individual | 37.7M | 7.7% | 2026-06-04 |
| 2026-06-11 | 13G | DCIG GP LLCother entity | 27.6M | 5.7% | 2026-06-04 |
| 2026-06-11 | 13G | DCIG Capital Master Fund LPother entity | 27.6M | 5.7% | 2026-06-04 |
| 2026-06-09 | 13G | Context Capital Management, LLCinvestment adviser, other entity | 48.8M | 9.9% | 2026-06-04 |
| 2026-06-09 | 13G | Michael S. Rosenparent holding company, individual | 48.8M | 9.9% | 2026-06-04 |
| 2026-06-09 | 13G | William D. Fertigparent holding company, individual | 48.8M | 9.9% | 2026-06-04 |
| 2026-06-09 | 13G | Charles E. Carnegieparent holding company, individual | 48.8M | 9.9% | 2026-06-04 |
| 2026-06-09 | 13G | Context Partners Master Fund, L.P.partnership | 48.8M | 9.9% | 2026-06-04 |
| 2026-05-14 | 13G/Ano. 2 | Octagon Capital Advisors LPinvestment adviser, partnership | 9.0M | 3.8% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 2 | Octagon Investments Master Fund LPpartnership, other entity | 9.0M | 3.8% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 2 | Ting Jiaparent holding company, individual | 9.0M | 3.8% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 6 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-24 | 13D/Ano. 1 | Growth Equity Opportunities 18 VGE, LLCother entity | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | NEA 18 Venture Growth Equity, L.P.partnership | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | NEA Partners 18 VGE, L.P.partnership | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | NEA 18 VGE GP, LLCother entity | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | Ali Behbahaniindividual | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | Carmen Changindividual | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | Anthony A. Florence, Jr.individual | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | Mohamad H. Makhzoumiindividual | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | Edward T. Mathersindividual | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | Scott D. Sandellindividual | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | Paul Walkerindividual | 4.1M | 1.7% | 2026-02-23 |
| 2026-02-24 | 13D/Ano. 1 | Rick Yangindividual | 4.1M | 1.7% | 2026-02-23 |
13F holders
Tracked managers holding GOSS at their latest 13F. JSON5 of the 30 tracked managers held GOSS at their latest 13F, $12.8M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $6.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 41.0M | $6.7M | 0.00% | +40.6M |
| AQR Capital Management | 2026-06-30 | 15.6M | $2.6M | 0.00% | +5.5M |
| Renaissance Technologies | 2026-06-30 | 11.6M | $1.9M | 0.00% | +10.4M |
| Two Sigma Investments | 2026-06-30 | 7.4M | $1.2M | 0.00% | +2.7M |
| Millennium Management | 2026-06-30 | 2.4M | $395K | 0.00% | +2.2M |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Gossamer Bio in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Gossamer Bio (GOSS), SEC CIK 1728117, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-01-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 1728117Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of GOSS is sold short?
1,436,240 shares were held short at the 2026-10-15 settlement, 5.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is GOSS's daily short volume?
On 2026-11-02, 42,629 of the 78,861 GOSS shares reported to FINRA were sold short, 54.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does GOSS have fails to deliver?
The SEC's latest file shows 12,724 GOSS shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are GOSS insiders buying or selling?
No open-market insider trades were reported for GOSS in the last 90 days. The most recent filings are listed below. Latest filing: Smith Robert Paul JR (Chief Commercial Officer) on 2026-01-02.
Who owns 5% or more of GOSS?
14 holders report 5% or more of GOSS in their latest filing, all on Schedule 13G (passive). The largest reported stake is 683 Capital Partners, LP at 10.0% of the class (49,868,571 shares), filed 2026-06-11 for an event on 2026-06-04.
Which tracked 13F managers own GOSS?
5 of the 30 tracked 13F managers held GOSS shares at their latest filing, $12.8M in all. The largest: D. E. Shaw & Co. (41.0M shares, $6.7M), Cliff Asness's AQR Capital Management (15.6M shares, $2.6M), Renaissance Technologies (11.6M shares, $1.9M), Two Sigma Investments (7.4M shares, $1.2M), Izzy Englander's Millennium Management (2.4M shares, $395K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.